newsfilter
← Latest News
GlobeNewswire·

BlossomHill Therapeutics to Present at Guggenheim’s 3rd Annual Healthcare Innovations Conference

  • BlossomHill Therapeutics (NASDAQ: BLSM) announced participation in Guggenheim's 3rd Annual Healthcare Innovations Conference at the Intercontinental Boston.
  • Management will hold a fireside chat on Tuesday, November 10, 2026, at 3:00 pm Eastern Time, with one-on-one investor meetings also scheduled.
  • An audio webcast of the fireside chat will be available on the company's investor website, with an archived replay accessible for 90 days.
  • The company is led by industry veteran J. Jean Cui, Ph.D., who has a track record of three FDA-approved drugs.
  • Lead clinical program BH-30643 is an orally bioavailable, brain-active, mutant-selective OMNI-EGFR inhibitor for EGFR-mutant non-small cell lung cancer that received Fast Track designation for the C797S resistance population.
  • Clinical development is ongoing for BH-30236, a macrocyclic CDC-like kinase inhibitor for relapsed or refractory acute myeloid leukemia & higher-risk myelodysplastic syndromes.
  • The pipeline includes preclinical BH-501284, a pan-KRAS Switch-II inhibitor for potential development in diverse KRAS-mutant tumors.
  • BlossomHill Therapeutics is headquartered in San Diego, California.